Team develops psoriasis drug

Mar 20, 2013

Ben-Gurion University of the Negev (BGU) researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis. The finding was reported in a new paper published in Chemistry and Biology.

Psoriasis is a chronic, non-contagious disease characterized by inflamed lesions covered with silvery-white scabs of dead skin. An auto-immune disease, psoriasis affects at least four million Americans. It is caused by the disturbance in the natural balance between pro-inflammatory signals and signals that inhibit inflammation.

One of the key signals involved in the progression of psoriasis is the Interleukin 17 (IL-17). The research team developed a method to inhibit IL-17 pro-inflammatory signals and proved that their engineered receptor, IL-17R, is highly effective in reducing IL-17 induced inflammatory signals in mice models. Moreover, injection of the receptor into a mouse model with acute human psoriasis eliminated the symptoms, essentially curing the disease.

"Using directed evolution to improve the properties of the IL-17 receptor, we have created engineered mutants that might prove there is a viable treatment for patients with severe psoriasis that do not respond to current drugs," explains Dr. Amir Aharoni, one of the researchers in BGU's Department of Life Sciences and the National Institute for Biotechnology in the Negev.

"Since the directed evolution method can be applied to other receptors involved in and cancer, I believe that we are just starting to unravel the potential of this approach," Aharoni adds.

Directed evolution is an iterative Darwinian optimization process used in whereby the fittest variants are selected from a collection of . Improved variants are identified and isolated by screening or selection for the property of interest. This approach is particularly advantageous in cases in which no prior knowledge of a protein's mechanism and structure is available.

The other researchers credited in "Directed Evolution of a Soluble Human IL-17A Receptor for the Inhibition of Psoriasis Plaque Formation in a Mouse Model" are BGU's Dr. Marianna Zaretsky and Teva researchers Dr. Liora Sklair-Tavron, Dr. Joel Kaye and Revital Etzyoni.

Explore further: Researchers create designer 'barrel' proteins

add to favorites email to friend print save as pdf

Related Stories

Protein may be key to psoriasis and wound care

Jun 21, 2012

Psoriasis is an autoimmune disorder in which skin cells proliferate out of control. For some hard-to-heal wounds, the problem is just the opposite: Restorative skin cells don't grow well or fast enough. In a paper published ...

Vitamin D analogs modulate immunity in psoriasis

Mar 09, 2012

(HealthDay) -- Vitamin D3 analogs modulate immunity in human psoriasis, inducing thymic stromal lymphopoietin (TSLP) and cathelicidin, according to a study published online March 2 in the British Journal of ...

Protein's new role discovered in autoimmune disease

Jan 02, 2008

Investigators at the University of Alabama at Birmingham (UAB) have identified the previously unknown role of a chemical 'messenger' leading to autoimmune disorders like rheumatoid arthritis and lupus.

Recommended for you

Amino acids key to new gold leaching process

18 hours ago

Curtin University scientists have developed a gold and copper extraction process using an amino acid–hydrogen peroxide system, which could provide an environmentally friendly and cheaper alternative to ...

Researchers create designer 'barrel' proteins

Oct 23, 2014

Proteins are long linear molecules that fold up to form well-defined 3D shapes. These 3D molecular architectures are essential for biological functions such as the elasticity of skin, the digestion of food, ...

User comments : 0